主页 文献库文献详情
PMID: 41984324 已发表 · epublish 英语

Frequency of bilateral prophylactic and contra-lateral risk-reducing mastectomies in women with germline PALB2 variants.

Familial cancer ·第 25 卷 ·第 2 期 ·2026-04-15

Corso G, La Vecchia C, Polizzi A, Magnoni F, Abruzzese G, Di Silvestre S, Pesapane F, Nicosia L, Bogani G, Intra M, Veronesi P, Galimberti V

摘要

Germline PALB2 variants confer a moderate/high-risk for breast cancer (BC). Recent reports described an increasing attention in suggesting bilateral prophylactic mastectomy (BPM), for healthy carriers, or contraleral risk-reducing mastectomy (CRRM) and/or therapeutic mastectomy for women with BC. In this study, we aimed to calculate systematically the overall number of these procedures reported in literature. We revised all articles using systematic research through the PUBMED database. Overall numbers, frequencies, geographic distribution, family history, and post-operative histopathological analysis of BPM or CRRM were the main outcomes considered. Among 51 studies, 10 articles fulfilled our aim. All BPM or CRRM were performed in North America. One-hundred and forty-two (6.6%) were PALB2 positive, from 2,135 tested women; a total of 84 women were treated, 35 (41.7%) were healthy carriers and 49 (58.3%) received a CRRM for a previous or contextual diagnosis of BC, respectively. A positive family history was reported in 80% of these groups, and a post-operative tumor was identified in 2.6% of breast specimens. In conclusion, very few studies are reported, only in North America, but about of 2/3 (~ 60%) of the screened women received BPM or CRRM, with a high familial history for BC and a low detection rate of tumor in breast post-operative specimens.

关键词
PALB2 gene germline mutations prophylactic mastectomy risk-reducing mastectomy
文献信息
期刊
Familial cancer
期刊简称
Fam Cancer
ISSN
1573-7292
发表日期
2026-04-15
语言
英语
国家/地区
Netherlands
NLM ID
100898211
分析服务
分析服务

联系地址

山东省济南市章丘区文博路2号

齐鲁师范学院 genelibs生信实验室

山东省济南市高新区舜华路750号

大学科技园北区F座4单元2楼

电话: 0531-88819269

微信公众号

关注微信订阅号,实时查看信息,关注医学生物学动态。


商务邮箱

E-mail: product@genelibs.com